	Efectivo Y Equivalentes		Fecha
ALKERMES	USD 388.57M	227.88M	2025-12
Alnylam Pharmaceuticals	USD 1.66B	167M	2025-12
Amarin	USD 122.8M	25.08M	2025-09
ANI Pharmaceuticals	USD 285.58M	22.98M	2025-12
Anika Therapeutics	USD 57.99M	4.82M	2025-09
Arrowhead Research	USD 201.64M	112.94M	2025-12
Eisai	JPY 301.65B	16.27B	2025-09
Emergent BioSolutions	USD 111.7M	23.9M	2023-12
Esperion Therapeutics	USD 92.45M	6.39M	2025-09
GlaxoSmithKline	GBP 3.3B	303M	2025-09
Heron Therapeutics	USD 43.07M	26.55M	2025-09
Insmed	USD 510.44M	175.68M	2025-12
Ligand Pharmaceuticals	USD 174.93M	489.59M	2025-12
Merck	USD 18.17B	10.16B	2025-09
Nektar Therapeutics	USD 41.03M	1.96M	2025-09
Neurocrine Biosciences	USD 713M	372.8M	2025-12
Omeros	USD 1.9M	2.36M	2025-06
Pacira	USD 158.54M	10.96M	2025-12
Regeneron Pharmaceuticals	USD 18.87B	16.36B	2025-12
Roche Holding	CHF 7.55B	579M	2025-06
Sangamo BioSciences	USD 38.34M	13.16M	2025-06
Surmodics	USD 36.11M	11.81M	2024-09
Ultragenyx Pharmaceutical	USD 202.51M	36.4M	2025-09
Veracyte	USD 362.58M	47M	2025-12
Vertex Pharmaceuticals	USD 6.61B	321.1M	2025-12

Heron Therapeutics Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.